Long-term efficacy of formoterol compared to salbutamol View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1990-12

AUTHORS

P. R. Hekking, F. Maesen, A. Greefhorst, J. Prins, Y. Tan, P. Zweers

ABSTRACT

In a randomized, double-blind, between-patient, multicenter study in 301 patients with ROAD, the efficacy and tolerability of the new long-acting selectiveβ2-sympathicomimetic drug formoterol (12µg inhalation b.i.d.) was compared with salbutamol (200µg inhalation q.i.d.). There was no statistically significant (s.s.) difference in acute reversibility and long-term efficacy of both drugs, measured by the point in time of expected maximal effect. However, formoterol had a highly s.s. longer duration of action than salbutamol, as shown by peak expiratory flow (PEF) measurements: the overall mean morning PEF in the formoterol group was 341 L/min.14 h after the last taken dose and in the salbutamol group this measure was 304 L/min9 h after the last dose. The patients taking formoterol had s.s. less asthma attacks and needed s.s. less rescue medication than those taking salbutamol. In the global assessment of efficacy, formoterol was accepted as being s.s. better (“very good” + “good”: 76%) than salbutamol (“very good” + “good”: 50%). The tolerability of each drug, as reflected by adverse reactions and global assessment, was equally good in both groups. Ninety-one percent of the patients in the formoterol group wanted to receive the same drug again versus 79% in the salbutamol group. More... »

PAGES

76-82

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02718117

DOI

http://dx.doi.org/10.1007/bf02718117

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012000274

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1974686


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Inhalation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Airway Resistance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Albuterol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bronchodilator Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delayed-Action Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ethanolamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Forced Expiratory Volume", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Formoterol Fumarate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Long-Term Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Diseases, Obstructive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peak Expiratory Flow Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hekking", 
        "givenName": "P. R.", 
        "id": "sg:person.01217467714.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217467714.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maesen", 
        "givenName": "F.", 
        "id": "sg:person.07672177314.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07672177314.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greefhorst", 
        "givenName": "A.", 
        "id": "sg:person.01141121675.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141121675.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Prins", 
        "givenName": "J.", 
        "id": "sg:person.0610312214.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610312214.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tan", 
        "givenName": "Y.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zweers", 
        "givenName": "P.", 
        "id": "sg:person.01270703304.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270703304.03"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1990-12", 
    "datePublishedReg": "1990-12-01", 
    "description": "In a randomized, double-blind, between-patient, multicenter study in 301 patients with ROAD, the efficacy and tolerability of the new long-acting selective\u03b22-sympathicomimetic drug formoterol (12\u00b5g inhalation b.i.d.) was compared with salbutamol (200\u00b5g inhalation q.i.d.). There was no statistically significant (s.s.) difference in acute reversibility and long-term efficacy of both drugs, measured by the point in time of expected maximal effect. However, formoterol had a highly s.s. longer duration of action than salbutamol, as shown by peak expiratory flow (PEF) measurements: the overall mean morning PEF in the formoterol group was 341 L/min.14 h after the last taken dose and in the salbutamol group this measure was 304 L/min9 h after the last dose. The patients taking formoterol had s.s. less asthma attacks and needed s.s. less rescue medication than those taking salbutamol. In the global assessment of efficacy, formoterol was accepted as being s.s. better (\u201cvery good\u201d + \u201cgood\u201d: 76%) than salbutamol (\u201cvery good\u201d + \u201cgood\u201d: 50%). The tolerability of each drug, as reflected by adverse reactions and global assessment, was equally good in both groups. Ninety-one percent of the patients in the formoterol group wanted to receive the same drug again versus 79% in the salbutamol group.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf02718117", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054004", 
        "issn": [
          "0341-2040", 
          "1432-1750"
        ], 
        "name": "Lung", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "168"
      }
    ], 
    "keywords": [
      "long-term efficacy", 
      "formoterol group", 
      "salbutamol group", 
      "global assessment", 
      "peak expiratory flow measurements", 
      "mean morning PEF", 
      "less rescue medication", 
      "expiratory flow measurements", 
      "acute reversibility", 
      "rescue medication", 
      "morning PEF", 
      "last dose", 
      "multicenter study", 
      "asthma attacks", 
      "adverse reactions", 
      "formoterol", 
      "same drug", 
      "maximal effect", 
      "patients", 
      "salbutamol", 
      "longer duration", 
      "efficacy", 
      "tolerability", 
      "drugs", 
      "significant differences", 
      "dose", 
      "group", 
      "medications", 
      "assessment", 
      "flow measurements", 
      "duration", 
      "percent", 
      "min", 
      "PEF", 
      "differences", 
      "study", 
      "action", 
      "measures", 
      "effect", 
      "time", 
      "reversibility", 
      "attacks", 
      "reaction", 
      "point", 
      "measurements", 
      "road"
    ], 
    "name": "Long-term efficacy of formoterol compared to salbutamol", 
    "pagination": "76-82", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012000274"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02718117"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1974686"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02718117", 
      "https://app.dimensions.ai/details/publication/pub.1012000274"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_253.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf02718117"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02718117'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02718117'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02718117'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02718117'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      20 PREDICATES      96 URIs      88 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02718117 schema:about N06f5cca5b04e48c9a29df76954e13111
2 N08736c2cfd7346549643c8157078d211
3 N19b95d679d4d483fbf4b8937e9886a8f
4 N25b4f2d605b74ce3b6ac12e2b63bc48b
5 N3584f3bef3264330ad2c3f8bf9a6a2e8
6 N3751f9f9e2234a75b29a2eb575c914b7
7 N38a77559c2204bf2a4bf89fd712bed25
8 N4358d0ee6ce9407481b2573e0deb1c11
9 N453b4ed29d0f404fb58f68b2a32e5d01
10 N521f8524bd124c3d9b4eed6b63bb0de8
11 N548c167bde30455f9f22be089f3ab794
12 N55c73f183a9844bb92f2680850b2d479
13 N65bb9b43d3834abe8bf0c1febc2a59e7
14 N6fb3ea53e40d4235a915aff4d95454fb
15 N73efabfa95ed47e38eaa8022ff0b2c71
16 N928664071018454abc21e43f5c42acca
17 N9d03fd226c39431b860b79c7469c75f5
18 Nba79cdf18e4e426e8b8c4b45bb2ba822
19 Nc0e8d49b1b67461bade4fdfdedfd45e9
20 Nc179a1a7faba4a49897ac0edab8b09e9
21 Nd6f10e46b0814ef792835f15509dbfa7
22 Ne08377675bbb436988edb9add482580b
23 Ne26633fde2df4ae09d0724ab52157c99
24 Nf4d633c7f3a3447da3228b2fca7a07c9
25 anzsrc-for:11
26 anzsrc-for:1115
27 schema:author N75eebd912d1f433682cb0e82251bd5a3
28 schema:datePublished 1990-12
29 schema:datePublishedReg 1990-12-01
30 schema:description In a randomized, double-blind, between-patient, multicenter study in 301 patients with ROAD, the efficacy and tolerability of the new long-acting selectiveβ2-sympathicomimetic drug formoterol (12µg inhalation b.i.d.) was compared with salbutamol (200µg inhalation q.i.d.). There was no statistically significant (s.s.) difference in acute reversibility and long-term efficacy of both drugs, measured by the point in time of expected maximal effect. However, formoterol had a highly s.s. longer duration of action than salbutamol, as shown by peak expiratory flow (PEF) measurements: the overall mean morning PEF in the formoterol group was 341 L/min.14 h after the last taken dose and in the salbutamol group this measure was 304 L/min9 h after the last dose. The patients taking formoterol had s.s. less asthma attacks and needed s.s. less rescue medication than those taking salbutamol. In the global assessment of efficacy, formoterol was accepted as being s.s. better (“very good” + “good”: 76%) than salbutamol (“very good” + “good”: 50%). The tolerability of each drug, as reflected by adverse reactions and global assessment, was equally good in both groups. Ninety-one percent of the patients in the formoterol group wanted to receive the same drug again versus 79% in the salbutamol group.
31 schema:genre article
32 schema:isAccessibleForFree false
33 schema:isPartOf Nccf7557a9b2344e4837cd9cf555fc5f0
34 Nf86ba6f8a973446990fe65486b1a4acb
35 sg:journal.1054004
36 schema:keywords PEF
37 action
38 acute reversibility
39 adverse reactions
40 assessment
41 asthma attacks
42 attacks
43 differences
44 dose
45 drugs
46 duration
47 effect
48 efficacy
49 expiratory flow measurements
50 flow measurements
51 formoterol
52 formoterol group
53 global assessment
54 group
55 last dose
56 less rescue medication
57 long-term efficacy
58 longer duration
59 maximal effect
60 mean morning PEF
61 measurements
62 measures
63 medications
64 min
65 morning PEF
66 multicenter study
67 patients
68 peak expiratory flow measurements
69 percent
70 point
71 reaction
72 rescue medication
73 reversibility
74 road
75 salbutamol
76 salbutamol group
77 same drug
78 significant differences
79 study
80 time
81 tolerability
82 schema:name Long-term efficacy of formoterol compared to salbutamol
83 schema:pagination 76-82
84 schema:productId N21c5c37c137b47bcb4bcd65f4de8d80d
85 Nc1118629c2974f848481b159ac97e4bf
86 Nc17f4b60cacb4e4387fa1466b27ed995
87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012000274
88 https://doi.org/10.1007/bf02718117
89 schema:sdDatePublished 2022-09-02T15:47
90 schema:sdLicense https://scigraph.springernature.com/explorer/license/
91 schema:sdPublisher Ndcd371241abc4928a4e470a28e64fc23
92 schema:url https://doi.org/10.1007/bf02718117
93 sgo:license sg:explorer/license/
94 sgo:sdDataset articles
95 rdf:type schema:ScholarlyArticle
96 N06f5cca5b04e48c9a29df76954e13111 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Ethanolamines
98 rdf:type schema:DefinedTerm
99 N08736c2cfd7346549643c8157078d211 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Airway Resistance
101 rdf:type schema:DefinedTerm
102 N19b95d679d4d483fbf4b8937e9886a8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Albuterol
104 rdf:type schema:DefinedTerm
105 N20f5634cb16548e08b43232bc822f82f rdf:first sg:person.01270703304.03
106 rdf:rest rdf:nil
107 N21c5c37c137b47bcb4bcd65f4de8d80d schema:name doi
108 schema:value 10.1007/bf02718117
109 rdf:type schema:PropertyValue
110 N21d99e472c654613b26bccf17577e9ba rdf:first sg:person.0610312214.35
111 rdf:rest N6867dba97ead4685bdfb574226086441
112 N25b4f2d605b74ce3b6ac12e2b63bc48b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Adrenergic beta-Agonists
114 rdf:type schema:DefinedTerm
115 N3584f3bef3264330ad2c3f8bf9a6a2e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Male
117 rdf:type schema:DefinedTerm
118 N3751f9f9e2234a75b29a2eb575c914b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Asthma
120 rdf:type schema:DefinedTerm
121 N38048570f89649b083e4c2b36fc69f58 rdf:first sg:person.01141121675.44
122 rdf:rest N21d99e472c654613b26bccf17577e9ba
123 N38a77559c2204bf2a4bf89fd712bed25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Formoterol Fumarate
125 rdf:type schema:DefinedTerm
126 N3db42b27df834d40bcdfbd03256d5790 rdf:first sg:person.07672177314.29
127 rdf:rest N38048570f89649b083e4c2b36fc69f58
128 N4358d0ee6ce9407481b2573e0deb1c11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Administration, Inhalation
130 rdf:type schema:DefinedTerm
131 N453b4ed29d0f404fb58f68b2a32e5d01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Multicenter Studies as Topic
133 rdf:type schema:DefinedTerm
134 N521f8524bd124c3d9b4eed6b63bb0de8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 N548c167bde30455f9f22be089f3ab794 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Forced Expiratory Volume
139 rdf:type schema:DefinedTerm
140 N55c73f183a9844bb92f2680850b2d479 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Long-Term Care
142 rdf:type schema:DefinedTerm
143 N65bb9b43d3834abe8bf0c1febc2a59e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Aged
145 rdf:type schema:DefinedTerm
146 N6867dba97ead4685bdfb574226086441 rdf:first Nd57c9680f42d4143b207d86768cfe60f
147 rdf:rest N20f5634cb16548e08b43232bc822f82f
148 N6fb3ea53e40d4235a915aff4d95454fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Peak Expiratory Flow Rate
150 rdf:type schema:DefinedTerm
151 N73efabfa95ed47e38eaa8022ff0b2c71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Delayed-Action Preparations
153 rdf:type schema:DefinedTerm
154 N75eebd912d1f433682cb0e82251bd5a3 rdf:first sg:person.01217467714.63
155 rdf:rest N3db42b27df834d40bcdfbd03256d5790
156 N928664071018454abc21e43f5c42acca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Drug Administration Schedule
158 rdf:type schema:DefinedTerm
159 N9d03fd226c39431b860b79c7469c75f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Bronchodilator Agents
161 rdf:type schema:DefinedTerm
162 Nba79cdf18e4e426e8b8c4b45bb2ba822 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Lung Diseases, Obstructive
164 rdf:type schema:DefinedTerm
165 Nc0e8d49b1b67461bade4fdfdedfd45e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Adult
167 rdf:type schema:DefinedTerm
168 Nc1118629c2974f848481b159ac97e4bf schema:name dimensions_id
169 schema:value pub.1012000274
170 rdf:type schema:PropertyValue
171 Nc179a1a7faba4a49897ac0edab8b09e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Double-Blind Method
173 rdf:type schema:DefinedTerm
174 Nc17f4b60cacb4e4387fa1466b27ed995 schema:name pubmed_id
175 schema:value 1974686
176 rdf:type schema:PropertyValue
177 Nccf7557a9b2344e4837cd9cf555fc5f0 schema:issueNumber Suppl 1
178 rdf:type schema:PublicationIssue
179 Nd57c9680f42d4143b207d86768cfe60f schema:affiliation grid-institutes:grid.477310.6
180 schema:familyName Tan
181 schema:givenName Y.
182 rdf:type schema:Person
183 Nd6f10e46b0814ef792835f15509dbfa7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Adolescent
185 rdf:type schema:DefinedTerm
186 Ndcd371241abc4928a4e470a28e64fc23 schema:name Springer Nature - SN SciGraph project
187 rdf:type schema:Organization
188 Ne08377675bbb436988edb9add482580b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Randomized Controlled Trials as Topic
190 rdf:type schema:DefinedTerm
191 Ne26633fde2df4ae09d0724ab52157c99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Middle Aged
193 rdf:type schema:DefinedTerm
194 Nf4d633c7f3a3447da3228b2fca7a07c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Female
196 rdf:type schema:DefinedTerm
197 Nf86ba6f8a973446990fe65486b1a4acb schema:volumeNumber 168
198 rdf:type schema:PublicationVolume
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
203 schema:name Pharmacology and Pharmaceutical Sciences
204 rdf:type schema:DefinedTerm
205 sg:journal.1054004 schema:issn 0341-2040
206 1432-1750
207 schema:name Lung
208 schema:publisher Springer Nature
209 rdf:type schema:Periodical
210 sg:person.01141121675.44 schema:affiliation grid-institutes:grid.477310.6
211 schema:familyName Greefhorst
212 schema:givenName A.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141121675.44
214 rdf:type schema:Person
215 sg:person.01217467714.63 schema:affiliation grid-institutes:grid.477310.6
216 schema:familyName Hekking
217 schema:givenName P. R.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217467714.63
219 rdf:type schema:Person
220 sg:person.01270703304.03 schema:affiliation grid-institutes:grid.477310.6
221 schema:familyName Zweers
222 schema:givenName P.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270703304.03
224 rdf:type schema:Person
225 sg:person.0610312214.35 schema:affiliation grid-institutes:grid.477310.6
226 schema:familyName Prins
227 schema:givenName J.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610312214.35
229 rdf:type schema:Person
230 sg:person.07672177314.29 schema:affiliation grid-institutes:grid.477310.6
231 schema:familyName Maesen
232 schema:givenName F.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07672177314.29
234 rdf:type schema:Person
235 grid-institutes:grid.477310.6 schema:alternateName Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands
236 schema:name Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...